Examkin

Soru

Zorluk: OrtaMedical History Evaluation

A 45-year-old male is evaluated in the infectious disease clinic for a 6-week history of low-grade fevers, drenching night sweats, a productive cough, and a 6.8-kg (15-lb) weight loss. His medical history is significant for severe, seropositive rheumatoid arthritis that has been well-controlled for the past two years. His current medications include methotrexate, infliximab, and as-needed ibuprofen. Social history reveals that he works as a landscaping contractor in Ohio. He returned from a one-week resort vacation in the Dominican Republic two months ago. He has a 10 pack-year history of cigarette smoking but quit 5 years ago. Vital signs show a temperature of 38.2°C (100.8°F), blood pressure of 122/78 mmHg, heart rate of 94/min, and respiratory rate of 18/min. Physical examination reveals bronchial breath sounds and post-tussive crackles in the right upper lung field. A chest radiograph demonstrates a 3.5-cm cavitary lesion in the right upper lobe without significant hilar adenopathy. When evaluating this patient's comprehensive history to establish the primary etiology of his current condition, which of the following elements is the most critical risk factor?

  1. A
    Employment as a landscaping contractor in Ohio
  2. Current treatment with infliximabCevap
  3. C
    Concurrent long-term use of methotrexate
  4. D
    Recent recreational travel to the Dominican Republic
  5. E
    Previous 10 pack-year history of cigarette smoking

Cevap

Current treatment with infliximab is the most critical historical risk factor for this patient's likely reactivation tuberculosis.
The correct answer identifies the use of infliximab as the most critical risk factor. Infliximab is a biologic agent that inhibits tumor necrosis factor-alpha (TNF-alpha). TNF-alpha plays an essential, non-redundant role in the formation and maintenance of caseating granulomas that encapsulate and contain Mycobacterium tuberculosis. When patients with latent tuberculosis infection (LTBI) are treated with TNF-alpha inhibitors, the granulomas break down, leading to rapid disease reactivation. The patient's clinical presentation—chronic cough, prominent constitutional symptoms, and an upper lobe cavitary lesion—is the classic manifestation of reactivation tuberculosis. Therefore, among all the details elicited during the medical history, the use of this specific biologic agent is the primary driver of the etiology.

Adım Adım Çözüm

1
Analyze the clinical presentation.
The patient has subacute constitutional symptoms (fevers, night sweats, weight loss) and a right upper lobe cavitary lung lesion.
Identifying the clinical syndrome points strongly toward chronic necrotizing pulmonary infections, classically reactivation tuberculosis (TB).
2
Evaluate the patient's comprehensive history for risk factors matching the presentation.
The history includes a biologic medication (infliximab), an endemic geographic exposure (Ohio/landscaping), a travel history (Dominican Republic), and a prior smoking history.
Differentiating incidental background findings from the primary disease driver is critical in complex medical histories.
3
Correlate the specific mechanism of action of the patient's medications with the suspected diagnosis.
Infliximab is a TNF-alpha inhibitor. TNF-alpha is required to maintain the integrity of macrophages and T-cells in the granulomas that sequester latent TB.
Disruption of TNF-alpha leads to granuloma breakdown and explosive reactivation of TB, making this the most potent and direct risk factor for his current condition.

Anahtar Kavram

Patients initiating tumor necrosis factor-alpha (TNF-alpha) inhibitors (e.g., infliximab) are at significantly increased risk for the reactivation of latent Mycobacterium tuberculosis due to the destabilization of protective granulomas.
Bu soruyu puanla

Konular

Medical History Evaluation

Bu konudan daha fazla soru